Retatrutide Explained: The Science Behind the Triple Agonist

Three takeaways

1. Retatrutide (Eli Lilly’s LY3437943) is a once-weekly investigational injectable that engages three receptors in one molecule — GLP-1, GIP and glucagon. It is not approved by any regulator anywhere, and Lilly states it is legally available only to participants in its clinical trials.
2. In published trials, adults with obesity lost an average of up to about a quarter of body weight over 80–104 weeks, and adults with type 2 diabetes saw A1C fall by up to 2 points in 40 weeks — with caveats: dose-related gut side effects, a hypotension and dysesthesia signal, and no proven reduction in cardiovascular events.
3. Lilly plans a US filing in the first quarter of 2027. Until a regulator rules, every “retatrutide” product offered online is not the medicine the trials tested.

Evidence type and regulatory status

Getting the name right

Retatrutide is the generic name of an experimental medicine developed by Eli Lilly and Company — the Indianapolis firm behind Zepbound and Mounjaro (research code LY3437943). It is a single molecule injected once a week under the skin, designed to act on three hormone receptors at once: the “triple agonist.”

A note on a name from the internet: “GLP-3” is not a scientific classification, and retatrutide is not “GLP-3.” There is no GLP-3 receptor. The molecule activates the GLP-1 receptor that semaglutide uses, the GIP receptor tirzepatide adds, plus the glucagon receptor. The “GLP-3” nickname circulates on seller pages because “the next GLP-1” is easy marketing; it has no scientific meaning and is not used again here.

Three receptors, one molecule

GLP-1, GIP and glucagon are natural hormones the gut and pancreas release after meals, and each signals something different:

• GLP-1 prompts insulin release when blood sugar is high, slows stomach emptying and quiets appetite signals in the brain.
• GIP also boosts insulin secretion and influences fat metabolism; in tirzepatide’s trials it appears to have softened the nausea burden of GLP-1 drugs alone.
• Glucagon, the counter-hormone that mobilises liver glucose between meals, interests researchers for its effects on energy expenditure and liver fat.

Retatrutide’s bet is that three receptors beat two. The results below are the test in humans; the mechanisms above are researchers’ explanations for what was observed — reasoning, not proof.

The clinical programme

Lilly’s Phase 3 work is large and fully in public view on the trial registry. The initial TRIUMPH programme began recruiting in 2023 and enrolled more than 5,800 people across four pivotal trials:

• TRIUMPH-1 (NCT05929066) — obesity or overweight with a weight-related comorbidity, but no diabetes: a master trial with two nested “basket” studies for knee osteoarthritis pain and obstructive sleep apnea. Completed; 2,339 randomised.
• TRIUMPH-2 (NCT05929079) — obesity or overweight plus type 2 diabetes. Completed; 1,152 randomised.
• TRIUMPH-3 (NCT05882045) — severe obesity (BMI ≥35) plus established cardiovascular disease. Completed; 1,949 randomised.
• TRIUMPH-4 (NCT05931367) — overweight or obesity with knee osteoarthritis. Completed.

Further trials probe the open questions: TRIUMPH-5 is head-to-head against tirzepatide (≈800, no longer recruiting), TRIUMPH-6 tests keeping weight off, -7/-8/-9 cover other populations and dosing schedules, and TRIUMPH-Outcomes (≈10,000, running to 248 weeks) asks whether the drug prevents heart and kidney events, not just weight. A second tranche, TRANSCEND, covers type 2 diabetes in medication-naive adults (>2,050 participants to date).

A study card for the pivotal obesity trial:

What the measured results show

The Phase 2 origin (NEJM 2023). A 338-person forerunner: 48 weeks on the 12 mg dose produced an average 24.2% loss versus 2.1% on placebo, with no plateau when the study ended. Side effects were mostly gastrointestinal; heart-rate rises peaked at 24 weeks then declined.

TRIUMPH-1 (obesity without diabetes). The largest average weight loss recorded in a pivotal obesity trial — the honest number depends on the analysis. Under the efficacy estimand (outcomes modelled as if everyone stayed on treatment), 4, 9 and 12 mg produced average losses of 19.0%, 25.9% and 28.3% versus 2.2% on placebo. The conservative treatment-regimen estimand — counting everyone who dropped out — gives 17.6%, 23.7% and 25.0% versus 3.9%. On the top dose, 45.3% lost at least 30% of their weight and 65.3% finished below the BMI-30 obesity threshold; in the 104-week extension, 12 mg averaged 30.3%. Measured beyond weight: triglycerides fell up to 41.0%, non-HDL cholesterol up to 24.2%, systolic blood pressure up to 12.3 mmHg, waist circumference up to 24.1 cm. In the osteoarthritis basket, WOMAC pain fell by up to 4.3 points (~73% from a baseline of 6.0); in the sleep apnea basket, the apnea–hypopnea index fell up to 36.1 events/hour (60.6%).

TRIUMPH-2 (with type 2 diabetes), published in The Lancet on 29 September 2026. In 1,152 adults, weight fell 18.8% at 12 mg versus 5.1% on placebo on the trial’s primary (treatment-regimen) analysis; Lilly’s efficacy-estimand headline was 20.8% versus 4.0%. A1C fell by up to 1.6 points from a 7.7% baseline — and thresholds tell the clearer story: up to 40% of retatrutide participants reached a normal A1C below 5.7%, and more than half of the 12 mg arm no longer met BMI criteria for obesity. An earlier, separate diabetes readout, TRANSCEND-T2D-1 (537 medication-naive adults, 40 weeks, The Lancet, June 2026), measured A1C drops up to 2.0 points versus 0.8 on placebo and weight loss up to 16.8%. Our trial-by-trial breakdown handles every estimand and its caveats.

TRIUMPH-3 (severe obesity plus cardiovascular disease) is topline-only. Lilly reported in July 2026 that both doses beat placebo — up to 22.6% average loss at 80 weeks versus 3.2% — with better blood pressure, lipids and hsCRP. Two qualifications: those numbers are not peer-reviewed yet, and the trial did not demonstrate a reduction in cardiovascular events — fewer events than anticipated occurred in both arms, so that question passes to TRIUMPH-Outcomes. Improved risk markers are not proven event reduction.

TRIUMPH-4 (knee osteoarthritis), announced December 2025. Both doses met the co-primary endpoints: average weight loss up to 28.7%, WOMAC pain down up to 4.5 points. Publication pending.

Two cautions apply throughout. Averages describe trial populations — individual results ranged widely. And weight is a proxy for what matters: joints, sleep, blood sugar and body composition, which deserves its own scrutiny. Against semaglutide and tirzepatide, no head-to-head trial has reported yet — cross-trial comparisons have known limits.

Adverse events and unknowns

• Gastrointestinal effects dominated. In TRIUMPH-1, nausea reached 42.4% on the top dose (vs 14.8% placebo), diarrhoea ~34%, constipation ~26%, vomiting ~25%. Most were mild-to-moderate, arose mainly during dose escalation, and most people continued.
• Discontinuations were dose-related: 4.1%, 6.9% and 11.3% at 4, 9 and 12 mg in TRIUMPH-1 (vs 4.9% placebo); 12% on 9 mg versus 5% placebo in TRIUMPH-2.
• Two signals need watching: hypotension (more frequent on top of some antihypertensives) and dysesthesia (odd skin sensations) ran at up to 6–7% on higher doses versus 0–1% placebo in the diabetes trials — unusual for this class, mostly mild and resolving, mechanism not fully understood. Urinary tract infections were also somewhat more frequent than placebo in TRIUMPH-1.
• Heart rate rises with dose (shown in Phase 2, peaking mid-trial) — a known GLP-1-class feature worth monitoring.
• The seven deaths across TRIUMPH-2’s arms were adjudicated unrelated to the drug.

Unknowns: safety beyond two years; weight regain after stopping; whether risk-factor improvements become fewer heart attacks, strokes and kidney failures (Outcomes trial, 248 weeks); the dysesthesia and hypotension mechanisms; pregnancy data; and class-typical rarer risks — gallbladder and pancreatic disease — that only longer studies can size.

Approval status (checked 13 October 2026)

No regulator anywhere — FDA, Europe’s EMA, South Africa’s SAHPRA — has approved retatrutide. Lilly is explicit that the molecule “cannot be legally sold or marketed for human use” and is “legally available only to participants in Lilly’s clinical trials.” With the five-trial data package, Lilly announced a Biologics License Application for the first quarter of 2027 (reaffirmed 29 September 2026), pending its manufacturing data package. A wrinkle remains: whether the FDA regulates the molecule as an ordinary drug or a biologic (a count of amino acids decides it) — contested in court through 2026 and unresolved, so even the filing route is not fully settled. Filing is not approval: review can take months, demand more data, or end in refusal.

Why online offers are not trial medicine

The only legal way to receive retatrutide today is inside a Lilly trial — supply manufactured under pharmaceutical conditions with every batch tested, dose-verified pens assigned under randomisation, medical screening, scheduled lab work, and every adverse event in an auditable system. None of that apparatus exists anywhere else.

Vials labelled “research use only,” unbranded pens or complete branded kits sold online are none of those things. No approved reference product exists to copy, so no buyer can verify what is in the vial, at what dose, or how it was made. A molecule that can cut 20–30% of body weight is not something to take without screening, lab work and follow-up; the hypotension and dysesthesia signals show why trials supervise escalation, and no online buyer gets that supervision. “Research use only” is, under the regulators’ own definitions, the opposite of a licence for human use — the full distinction is a study of its own. The science in this article belongs to the tested molecule; nothing an online seller ships inherits that record.

The bottom line

Retatrutide is the first triple agonist to reach the end of Phase 3, with unusually strong evidence for an investigational molecule and clear open questions — cardiovascular outcomes, durability, long-term safety. We update this page at material events, and our research newsletter carries those updates first — subscribe for research updates to be there when the next verdict lands.

Known limitations

• TRIUMPH-3 and TRIUMPH-4 are company topline announcements, not peer-reviewed papers; no p-values or full safety tables are public yet.
• Headlines quote the efficacy estimand; treatment-regimen figures — the whole randomised group’s experience — run about 3 points lower. Both are given above; news coverage rarely gives both.
• No head-to-head result versus semaglutide or tirzepatide exists yet (TRIUMPH-5 pending).
• Cross-trial comparisons involve different populations, years and analysis choices.
• Cardiovascular event benefit is unproven; the outcomes trial runs to 248 weeks.
• Long-term safety and durability remain open.
• Educational only, not personal medical advice; clinical content has not yet had qualified medical review.

FAQ

Is retatrutide approved? No — investigational everywhere as of 13 October 2026. Lilly’s first US filing is planned for Q1 2027, and a filing can fail.

Can I buy retatrutide? Not lawfully as a medicine. Lilly states it is available only to trial participants. Online vials, pens or “GLP-3”-branded kits are unapproved substances of unverified content — not trial medicine.

Why is it called “GLP-3”? Marketing, not science: no GLP-3 receptor exists. Retatrutide acts on GLP-1, GIP and glucagon receptors.

How does it compare with tirzepatide? Tirzepatide engages GLP-1 and GIP; retatrutide adds glucagon. Trials suggest a larger average effect, but no head-to-head has reported yet.

Suggest a correction

Use the correction link at the foot of this page. Substantive corrections are dated and logged, never silently replaced.

Sources

1. Eli Lilly news release, 21 May 2026 — TRIUMPH-1 topline (investor.lilly.com): average weight losses, thresholds, extension results.
2. Eli Lilly news release, 6 June 2026 (ADA Scientific Sessions) — TRIUMPH-1 basket endpoints (WOMAC, AHI) and TRANSCEND-T2D-1, with adverse-event tables.
3. Jastreboff AM, et al. “Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity.” New England Journal of Medicine, published online 29 September 2026. DOI: 10.1056/NEJMoa2604169.
4. Bellido V, le Roux CW, Ekinci EI, et al. “Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2).” The Lancet, published online 29 September 2026. DOI: 10.1016/S0140-6736(26)01861-1.
5. Eli Lilly news release, 29 September 2026 — TRIUMPH-2 detailed results (EASD, Milan), TRIUMPH-1 estimand tables, Q1 2027 filing reaffirmed.
6. Eli Lilly news release, 23 July 2026 — TRIUMPH-2/TRIUMPH-3 topline; BLA planned Q1 2027; molecule “cannot be legally sold or marketed for human use.”
7. Eli Lilly news release, 19 March 2026 — TRANSCEND-T2D-1 topline (n=537; A1C, weight, dysesthesia, discontinuations).
8. Eli Lilly news release, 11 December 2025 — TRIUMPH-4 topline; medical.lilly.com FAQ on TRIUMPH-4 preliminary results (2026).
9. Sur JB, Kaplan LM, Frías JP, et al. “Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.” New England Journal of Medicine 2023;389:514–526. DOI: 10.1056/NEJMoa2301972 (NCT04881760).
10. ClinicalTrials.gov registry records (accessed 13 October 2026): NCT05929066, NCT05929079, NCT05882045, NCT05931367 (completed); NCT06662383 (vs tirzepatide, active); NCT06383390 (TRIUMPH-Outcomes, 248 weeks); NCT06859268 (maintenance).
11. Eli Lilly, “What to know about retatrutide” (lilly.com) — standing investigational-status statement; manufacturer content read alongside the independent papers above.

Related articles: Retatrutide Trial Results: What the Headlines Leave Out (05) · Semaglutide, Tirzepatide and Retatrutide (06) · Weight Loss and Muscle: Why Body Composition Matters (07) · Approved Medicines, Clinical Trials and “Research Use Only” (03)

Suggest a correction